Compare LZB & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LZB | ATAI |
|---|---|---|
| Founded | 1927 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1994 | 2025 |
| Metric | LZB | ATAI |
|---|---|---|
| Price | $35.97 | $4.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $42.50 | $15.75 |
| AVG Volume (30 Days) | 328.7K | ★ 4.0M |
| Earning Date | 02-17-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $2,349,433,000.00 | $4,089,000.00 |
| Revenue This Year | $1.89 | N/A |
| Revenue Next Year | $2.09 | N/A |
| P/E Ratio | $21.75 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $29.03 | $1.29 |
| 52 Week High | $44.49 | $6.73 |
| Indicator | LZB | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 66.98 | 76.83 |
| Support Level | $35.32 | $4.96 |
| Resistance Level | $39.71 | $5.34 |
| Average True Range (ATR) | 0.83 | 0.25 |
| MACD | 0.52 | 0.11 |
| Stochastic Oscillator | 91.47 | 73.54 |
La-Z-Boy Inc is a U.S.-based company that manufactures, distributes, and retails upholstery furniture products. It is a producer of reclining chairs and distributors of residential furniture in the U.S. The company chiefly operates in the United States but also has secondary operations in Canada and other countries. The company's reportable segments include the Wholesale segment, which manufactures and imports upholstered furniture; Retail, which sells upholstered and case goods furniture to the end consumer and corporate and others. The majority of the company's revenue is derived from its Wholesale segment.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.